INFORMATION ON THIS WEBSITE IS INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY

Schizophrenia

IN.SIGHT

Adverse event reporting information can be found in the footer of this webpage

About IN.SIGHT

On this page you will find presentations, symposia, and videos from the 2023 IN.SIGHT event, organised and funded by ROVI®.

The “Inpatient Schizophrenia: Innovation, Guidance and new Horizons in Treatment” (IN.SIGHT) 2-day educational event tackled the key issues in managing inpatient schizophrenia. Schizophrenia remains a complex and challenging condition to treat, and persistent unmet needs in clinical practice make our deeper understanding of its management crucially important.1-3

Among these unmet needs is the underutilisation of antipsychotic medications, and of long-acting injectable (LAI) antipsychotics in particular, despite a growing body of evidence supporting their use.1 Appropriate and timely use of second generation LAI antipsychotics (SGA-LAIs) and clozapine is among the identified modifiable factors associated with excess mortality in schizophrenia.1 Adequate LAI trials are also an important step before diagnosing treatment-resistant schizophrenia,2 and together with clozapine, LAIs are the pharmacological treatments with the highest rates of prevention of relapse, significantly reducing the risk of rehospitalisation in schizophrenia compared with equivalent oral formulations.3 This is the backdrop to some of the topics which were explored during this educational event.

Faculty

References: 1. Correll CU, et al. World Psychiatry. 2022;21:248-271. 2. Howes OD, et al. Am J Psychiatry. 2017 Mar 1;174(3):216-229. 3. Tiihonen J, et al. JAMA Psychiatry. 2017;74(7):686-693.